Oral probiotic combination of Lactobacillus and Bifidobacterium alters the gastrointestinal microbiota during antibiotic treatment for Clostridium difficile infection
Autor: | Nasia Safdar, Shoshannah Eggers, Kimberly A. Dill-McFarland, Anna K. Barker, T. J. De Wolfe, Ashley E. Kates, Garret Suen |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2018 |
Předmět: |
0301 basic medicine
Administration Oral lcsh:Medicine law.invention Probiotic Lactobacillus acidophilus law Antibiotics Lactobacillus Ruminococcus Medicine and Health Sciences Medicine Bacteroides lcsh:Science Bifidobacterium Data Management Multidisciplinary biology Antimicrobials Gastrointestinal Microbiome Drugs Genomics 3. Good health Anti-Bacterial Agents Medical Microbiology Research Design Antibiotic transport Research Article Microbial Taxonomy Computer and Information Sciences Lactobacillus paracasei Clostridium Difficile Clinical Research Design Microbial Genomics Research and Analysis Methods Microbiology 03 medical and health sciences Microbial Control Genetics Humans Microbiome Taxonomy Pharmacology Bacteria business.industry Probiotics Gut Bacteria lcsh:R Organisms Biology and Life Sciences biology.organism_classification 030104 developmental biology Clostridium Infections lcsh:Q business |
Zdroj: | PLoS ONE, Vol 13, Iss 9, p e0204253 (2018) PLoS ONE |
ISSN: | 1932-6203 |
Popis: | Perturbations in the gastrointestinal microbiome caused by antibiotics are a major risk factor for Clostridium difficile infection (CDI). Probiotics are often recommended to mitigate CDI symptoms; however, there exists only limited evidence showing probiotic efficacy for CDI. Here, we examined changes to the GI microbiota in a study population where probiotic treatment was associated with significantly reduced duration of CDI diarrhea. Subjects being treated with standard of care antibiotics for a primary episode of CDI were randomized to probiotic treatment or placebo for 4 weeks. Probiotic treatment consisted of a daily multi-strain capsule (Lactobacillus acidophilus NCFM, ATCC 700396; Lactobacillus paracasei Lpc-37, ATCC SD5275; Bifidobacterium lactis Bi-07, ATCC SC5220; Bifidobacterium lactis B1-04, ATCC SD5219) containing 1.7 x 1010 CFUs. Stool was collected and analyzed using 16S rRNA sequencing. Microbiome analysis revealed apparent taxonomic differences between treatments and timepoints. Subjects administered probiotics had reduced Verrucomicrobiaceae at week 8 compared to controls. Bacteroides were significantly reduced between weeks 0 to 4 in probiotic treated subjects. Ruminococcus (family Lachnospiraceae), tended to be more abundant at week 8 than week 4 within the placebo group and at week 8 than week 0 within the probiotic group. Similar to these results, previous studies have associated these taxa with probiotic use and with mitigation of CDI symptoms. Compositional prediction of microbial community function revealed that subjects in the placebo group had microbiomes enriched with the iron complex transport system, while probiotic treated subjects had microbiomes enriched with the antibiotic transport system. Results indicate that probiotic use may impact the microbiome function in the face of a CDI; yet, more sensitive methods with higher resolution are warranted to better elucidate the roles associated with these changes. Continuing studies are needed to better understand probiotic effects on microbiome structure and function and the resulting impacts on CDI. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |